Merck Sinks 9.5% in a Week as It Scraps a Blood Cancer Drug and Healthcare Sells Off. Time to Buy?
Merck (MRK) shares dropped 9.5% last week after halting development of a blood cancer drug and a broader healthcare sell-off. The company won a German court case against Halozyme (HALO) but faces patent loss for Keytruda in 2028. Analysts expect 2027 earnings to recover to 2025 levels. Merck's stock is up 27% in 2026.
How this was made
The 30-second read
Why it matters
The combined news creates mixed sentiment; the drug stop is a negative catalyst, while the court win offers a modest positive offset.
Market read
Primary company news with material impact on Merck's valuation and potential ripple effects across the oncology sector.
What to watch
Merck's dividend increase and strong Q3 sales may support the stock despite the drug halt.
Background
Merck announced the cessation of its experimental blood‑cancer drug nemtabrutinib after a Phase 3 review and reported a German court decision favoring its Keytruda patent case against Halozyme.
Ticker impact
Merck stopped development of the blood‑cancer drug nemtabrutinib after a Phase 3 review, a fresh negative catalyst for the company.
likely modest downside as investors price in the loss of the nemtabrutinib program
The news is a primary disclosure of a discontinued drug program, a material event for a large pharma, and no comparable offsetting catalyst outweighs the negative impact.
Market effects
May pressure other oncology drug developers as pipeline risk reassessed.
US pharma stocks could see slight pullback.
Limited to biotech/healthcare investors worldwide.
Counterpoint
The court win and strong Keytruda pipeline could cushion the impact, presenting a buying opportunity on the dip.
Key entities
- CompanyMerck
US‑listed pharmaceutical giant (ticker MRK).




